15. Inclusion body myositis
39 clinical trials,   32 drugs   (DrugBank: 11 drugs),   11 drug target genes,   119 drug target pathways

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00079768
(ClinicalTrials.gov)
March 200412/3/2004Alemtuzumab to Treat Sporadic Inclusion Body MyositisEffects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological StudyMyositis, Inclusion BodyDrug: Alemtuzumab (Campath)National Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted25 Years80 YearsBoth20Phase 2United States